Jump to content
Counter Culture Labs
Pages for logged out editors
Help about MediaWiki
What links here
Get shortened URL
IGEM team meeting notes 5 26 14
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
fill this in!
= Agenda = * IP discussion with Yaasha * Ooh and aah over DNA distribution kit we just received from iGEM * Fundraising * DNA assembly methods Marc - fundraising video in progress, possibly done by Wednesday Advait and Fran - (Probably) Meeting at Biocurious this Wednesday at 7:00 pm to finalize. = IP stuff = Consensus: want to keep research open but should it be selectively open? (ie, not open to incumbents who may not share their research back with the community...or should large companies have to pay a fee?) Should we worry about market shares and competition in the future? (the Kraft monopoly scenario) Yaasha: no, if a big company starts pushing out smaller ones it will be on the basis of their innovation not ours concerns/cultural aims of the project that extend beyond getting more vegan cheese into the world: centralization of power; environmental impact of our actions; reshape the way GMO food is regarded, handled and treated in the U.S. Discussion about DPL option Yaasha Sabba prefers patent option as a way to protect work done by the group and give everybody recognition as coinventors DPL is not permanent - can decide to remove it from the pool later patent office doesn't have time to look at wikis...even if you want to have it open it is good to register with the PTO and abandon it Craig: prefers keeping everything open; brought up good point that our project does not involve novel techniques; what's goal of the team? Miyoko (from Fairfax): Ahnon emailed Miyoko requesting help regarding producing vegan cheese once we express the protein we need to put it into something miyokoskitchen.com Options a la Marc: # File a non-provisional patent application. Get it accepted. Then explicitly abandon the patent. # File a non-provisional patent application and stop doing anything, thus abandoning the patent. # 3rd party pre-grant review: 6 month period where patent is pending; can submit prior art; way of bringing thigs to the attention of people using PTO; but have to wait for someone else to file a patent, catch it, and with help of a lawyer file in response to the new patent Big Q: to patent or not to patent. Filing a provisional patent at this point would be shooting ourselves in the foot. What's the liklihood of an outside group affecting our group's ability to continue conducting research on this product beyond the iGEM competition? K-casein expression in e. coli is already patented provisional patent option: addresses 'first to file' concerns can lose the provisional if it lacks enough/appropriate information prior art: publically announced meet up group; personal witnesses to this meeting; here is what we said in our minutes today; everything we discussed today is prior art How do we execute the intellectual property internally? (next big hurdle) by patenting, giving yourselves the power to say 'open' or 'closed;' (BC or CCL or both?) conflict of interest statement prohibits any board members from being involved with projects that are not open-source another possible issue: anyone working with a formal lab (i.e. Patrik @ LLL) will have to show their employer any patents and have it approved as well techology transfer: additional concern associated with federally funded organizations sub-organization with separate by-laws and small board; only purpose of this sub-org would be to hold/file provisional patents/DPL Consensus to do 2 things: # write up... # attempt to either.....abandon DPL Linda Kahl US PTO: big change; $ from patent fees no longer all going to government; much of the fees are going to US PTOs new San Jose office Group in Ireland that has been contacting Patrik focused more on milk than the cheese have 30K in funding; backed by corporate investors (http://synbioaxlr8r.com/) = DNA Distribution Kit = http://parts.igem.org/Help:2014_DNA_Distribution To do: # Go through parts list; watch videos; download excel files listing components/details # Internal databases plasmid DB vector maps Open-source alternatives to File Maker Pro: http://www.osalt.com/filemaker http://alternativeto.net/software/filemaker-pro/ = Fundraising = this Wednesday; somewhere in Oakland; noonish - 5 pm; Marc, Francis, etc. finishing up filming fundraising video changing text/wording on crowd tilt page: writing an intro for a proposal - first sentence should explain your entire project contact Jing Fiver.com for professional voie over Video "rough draft" link (with footage and possible music): https://docs.google.com/file/d/0B4WT2XIBrqnScmZCLUFYOTFOWlU/edit This is not so much the actual video but more of a "practice" with some good footage and a possible music choice. Jamie: Contact David B at PETA.org Ashley: would have a problem working with PETA this a.m. Fran posted a fundraising video on SeaFile link to video with music: https://docs.google.com/file/d/0B4WT2XIBrqnScmZCLUFYOTFOWlU/edit = DNA Assembly Methods = Craig put together an awesome power point presentation: Powerpoint: https://docs.google.com/viewer?a=v&pid=forums&srcid=MDQ3ODI0ODE4NDM3NTM4NjIyMzUBMDM5OTQ5MTk5OTAwNDIzOTE2MjcBa0Z0ZTFkd2xycGdKATQBAXYy linkers == Traditional cloning == plasmid backbone: circular piece of DNA we're cloning into that has ab resistance, ORI, etc. http://help.teselagen.com/manual/section/8/ What RE sites can you use? RE sites can't be inside your DNA (will cute out GOI) Stoichiometry: important consideration when determining ideal plasmid backbone:GOI ratio If something goes wrong with ________ must use traditional cloning to fix it == Golden Gate Cloning == good for multiple sequence cloning you design DNA overhangs to ligate multiples pieces together in a strategic orientation no scar sequence introduced issues with scars occur when you're ligating together different protein domains same RE used for everything; restriction site is elminated from ligated product == BioBrick approach == use a few, specific restriction enzymes makes cloning easy if parts assembled on their own see http://parts.igem.org/Help:Standards/Assembly iGEM wants us to submit everything we do with BioBricks methods; different cloning methods are compatible with each other == SLIC: sequence and ligation independent cloning == one enzyme used for every reaction multi-step process; backbone vector contains sequences intrinsic to the plasmid backbone; GOI designed with same DNA at both ends throw in T4 DNA polymerase because it has 3' DNA exonuclease activity; eats up DNA from opposite ends of template strands e.coli (for example) repair machinery fills in gaps after ligation make constructs in e.coli and then express them in yeast == Gibson == three enzymes used for every reaction (more costly) one-step process Like SLIC except it uses T5 exonuclease (5' --> 3' activity; opposite of T4 used in SLIC) nicks repaired before they go into e. coli overhangs must lack secondary structure to avoid formation of hairpins which would compete with GOI for insertion into backbone only method with a theme song :) == GeneArt (not included in powerpoint) == Wrap-up & things to do: # creating cloning strategies on paper # make an excel sheet with all reagents; price break down; similar to spreadshet for DIY cloning class # update wiki with all work done individually or in groups; present updates to group meetings # finalize video and crowdtilt
Please note that all contributions to Counter Culture Labs are considered to be released under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) (see
Counter Culture Labs:Copyrights
for details). If you do not want your writing to be edited mercilessly and redistributed at will, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource.
Do not submit copyrighted work without permission!
(opens in new window)
Retrieved from "